Pancreatic Islet Cell Tumor Clinical Trials

Find Pancreatic Islet Cell Tumor Clinical Trials Near You

A Study of Second-Line Treatment Response and Resistance Mechanisms in Pancreatic Neuroendocrine Tumors With Liver Metastases Based on cfDNA and Single-Cell PBMC Multi-omics

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This prospective, non-randomized, concurrent parallel-controlled study will evaluate treatment response and resistance mechanisms in patients with pancreatic neuroendocrine tumors with liver metastases (pNET-LM) receiving second-line systemic therapy after failure of first-line treatment. Eligible patients will receive either lenvatinib combined with chemotherapy or chemotherapy alone according to the study protocol and clinical treatment strategy. The clinical efficacy and safety of the two treatment strategies will be evaluated using objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events. Peripheral blood samples will be collected before treatment, during early treatment, and at disease progression. Circulating cell-free DNA (cfDNA) and peripheral blood mononuclear cells (PBMCs) will be analyzed to investigate molecular and immune changes associated with treatment response, primary resistance, and acquired resistance. The study aims to identify potential biomarkers for predicting treatment response and to improve understanding of resistance mechanisms in pNET-LM.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Age 18 to 75 years.

• Histologically or cytologically confirmed pancreatic neuroendocrine tumor.

• Radiologically confirmed liver metastases.

• Disease progression or treatment failure after first-line systemic therapy, with eligibility for second-line treatment.

• At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Adequate hematologic, hepatic, and renal function as assessed by the investigator.

• Life expectancy of at least 12 weeks.

• Ability to understand and willingness to sign a written informed consent form.

Locations
Other Locations
China
Chinese Academy of Medical Sciences,Peking Union Medical College Hospital
RECRUITING
Beijing
Time Frame
Start Date: 2026-01-26
Estimated Completion Date: 2028-07-01
Participants
Target number of participants: 80
Treatments
Experimental: Lenvatinib Plus Chemotherapy
Active_comparator: Chemotherapy Alone
Sponsors
Leads: Peking Union Medical College Hospital

This content was sourced from clinicaltrials.gov